Project 61 Acquires Offshift to Launch First-Ever Free, Industry-Wide Health Platform for Truck Drivers
Truck drivers have the highest rates of obesity and diabetes of any occupation in the U.S.. This crisis is worsening as chronic disease continues to skyrocket. Project 61 is spearheading the Movement to reverse that trend.
Offshift's technology now powers the mobile platform delivering Project 61's mission - putting free, practical tools and a driver-led community directly into the hands of America's trucking workforce. The platform helps drivers build healthier habits around nutrition, movement, and sleep - three critical areas directly tied to longevity, energy, and safety.
'This is a game-changer for the Movement. If we're going to address this industry-wide health crisis at scale, technology has to lead the way,' said Jeremy Reymer, founder of Project 61. 'With the acquisition of Offshift, we're turning awareness into action through a proven solution that empowers drivers to take daily steps toward a longer, healthier life.'
Whether it's a five-minute workout from within their cab, healthier options at truck stops, or tracking sleep with a wearable, every feature is designed for the realities of life on the road.
'Offshift was born out of frustration. As a physical therapist, I saw what 20 to 30 years behind the wheel can do to a person's body - and how none of the available health solutions actually worked in the real world of trucking,' said Dr. Mark Manera, Founder of Offshift. 'We built Offshift to change that. Now, joining forces with Project 61 lets us turn that vision into reality for the entire trucking industry. Together, we're not just raising awareness about this health crisis - we're putting a proven solution into the hands of every driver in North America at no cost.'
Dr. Mark Manera will serve as President and Chief Health Officer of Project 61, working alongside founder and CEO Jeremy Reymer to lead this Movement forward. Industry-wide health challenges will be a cornerstone of the initiative, designed to foster community between drivers, companies, and families around shared health goals. The first challenge will launch October 1st.
Why This Matters
Investing in driver health is one of the smartest ways to reduce risk in trucking. When drivers are unhealthy, risk goes up - so do healthcare costs, workers comp claims, crash rates, and disability payouts. Poor health hurts more than drivers - it undermines every part of a carrier's operation.
But the reverse is also true: when drivers are healthier, they're safer, more alert, and more engaged. Fleets see stronger safety scores, lower turnover, and reduced exposure across the board.
And when we support drivers in living longer, healthier lives, we don't just protect them - we strengthen the entire supply chain and economy that depends on them.
Join the Movement
Project 61 is calling on the entire trucking industry and supply chain - motor carriers, vendors, insurance partners, and industry stakeholders - to step up.
How can you support the mission?
Start here: Sign The Trucker Health Pledge ( http://project-61.org/pledge ) - the industry's first public stand for driver health.
Then take the next step based on your role:
Trucking and insurance companies can offer this program to their drivers and also become Corporate Partners.
Any industry stakeholder can become a Corporate Partner or Individual Donor to directly help extend lives.
Media & Influencers can help amplify the message across the entire industry and beyond.
Truck drivers face the harshest health outcomes of any profession - and it's costing them years off their life. They've spent their careers delivering for everyone else. It's time the industry gives them something back: more life, more strength, and more time with the people who matter most.
When drivers are healthier, families are stronger, roads are safer, and companies thrive. It's time for the industry to invest in what matters most: the people behind the wheel.
About Project 61
Project 61 is a national 501(c)(3) nonprofit spearheading a Movement to improve the health and wellness of America's truck drivers. By raising awareness and providing the education, resources, and tools drivers need, Project 61 is confronting a crisis that has cut their life expectancy to just 61 years. The organization is building a nationwide community grounded in connection, habit change, and accountability. Through its free mobile app and a proven, practical roadmap for health on the road, Project 61 empowers drivers to take daily steps that can add years to their lives.
About Offshift
Founded in St. Louis, MO by Dr. Mark Manera and Maxime Devoge, Offshift was the first digital health platform designed specifically for truck drivers. It combined behavioral science, coaching, and technology to improve health outcomes in one of America's most underserved populations. Now, its legacy lives on as the foundation of Project 61's technology platform.
Media Contact:
Jeremy Reymer, [email protected], project-61.org
Contact Information:
Project 61, Inc.
Jeremy Reymer
317-339-5618
Contact via Email
project-61.org
[email protected]
Read the full story here: Project 61 Acquires Offshift to Launch First-Ever Free, Industry-Wide Health Platform for Truck Drivers
Press Release Distributed by PR.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
John Gleeson, attorney and resilient polio survivor, dies at 86
The polio that afflicted him as a boy never left John Gleeson, but it never held him back. "He's someone who just never let anything bring him down," Gerry Gleeson II said Saturday, July 26, adding that the disease essentially paralyzed his father for two years of his childhood. Polio caused some life-long mobility challenges — though no one could blame the disease for Gleeson's penchant for wearing black Gold Toe socks with shorts — but it also contributed to a resiliency that made an impression on his family. "There was no obstacle — nothing was going to hold him back from whatever he was going to achieve," his son said. Gleeson, who earned a law degree at night while working as a teacher, became a beloved raconteur known for welcoming a constellation of engaging conversationalists into his West Bloomfield home long before he died July 18 at the age of 86. While Gleeson loved being a lawyer — "he liked the intellectual challenge, he liked being in court, he liked being before a jury," his son said — he also loved holding court at home. Gleeson and his wife Mary Ellen, who died in 2018, hosted dinner gatherings in which the conversation flowed along with fine wine. "In addition to all his other fine qualities, he was a wine connoisseur," said Steve Fishman, a prominent defense attorney who got to know him through Gerry Gleeson who, like his father, became an attorney. Gleeson, Fishman said, had "an unbelievable wine cellar." The Gleesons' passion for the grape led them to spend many winters in Napa Valley, the region in northern California known for hundreds of vineyards. Gleeson, known to his granddaughters as "Papa," also savored spending time with family. Gerry Gleeson said that even though his father was a "fiercely competitive" attorney (he specialized in environmental law and represented businesses), "he'd make a point to be home early to be with family." Even though Gleeson favored the conservative Fox News network, his experience with polio made him an early proponent of the COVID-19 vaccine, his son said, adding that his dad was "first in line" when it became available. Reflecting on his father's life and the time they spent together, Gerry Gleeson said one of the things he'll miss most is "sitting around the grill shooting the breeze." Gleeson's survivors include son John and granddaughters Madeleine, Sydney and Margaux. Visitation will be Monday, July 28 from 9 a.m. to 10 a.m. at Holy Name Catholic Church, 630 Harmon, Birmingham, followed by a funeral mass at 10 a.m. M.L. Elrick is a Pulitzer Prize- and Emmy Award-winning investigative reporter, director of student investigative reporting program Eye On Michigan, and host of the ML's Soul of Detroit podcast. Contact him at mlelrick@ or follow him on X at @elrick, Facebook at ML Elrick and Instagram at ml_elrick. This article originally appeared on Detroit Free Press: John Gleeson, attorney and resilient polio survivor, dies at 86 Solve the daily Crossword
Yahoo
25 minutes ago
- Yahoo
FDA approves SetPoint's neuroimmune modulation device for RA treatment
The US Food and Drug Administration (FDA) has approved SetPoint Medical's implantable neuroimmune modulation device, SetPoint System, to treat moderate-to-severe rheumatoid arthritis (RA) in adults. The system is designed for individuals who are inadequately managed by or intolerant to current RA therapies such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). The system is said to activate the body's natural anti-inflammatory and immune-restorative pathways by delivering electrical stimulation to the vagus nerve once a day. The neurostimulation therapy can potentially provide an alternative treatment without immune-compromising risks. The FDA approval was based on the outcomes of the RESET-RA study, a 242-patient double-blind, randomised, sham-controlled trial, which showed the system's efficacy and safety in this patient group. Patients tolerated the device placement procedure and the stimulation therapy well, with a low incidence of related serious adverse events at 1.7%. SetPoint Medical CEO Murthy Simhambhatla said: 'The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases. 'We are committed to improving the health of people living with RA, and look forward to working with providers and payers to make our innovative therapy accessible to their patients. We plan to introduce the SetPoint System in targeted US cities this year, followed by expansion across the country starting in early 2026.' SetPoint Medical is also exploring the use of its neuroimmune modulation platform for other autoimmune diseases such as multiple sclerosis (MS) and Crohn's disease. In March 2024, the company's neuroimmune modulation device secured a breakthrough device designation to treat relapsing-remitting MS. "FDA approves SetPoint's neuroimmune modulation device for RA treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
IDEXX Laboratories Raises Full-Year Outlook Following Second-Quarter Beat
IDEXX Laboratories (IDXX) lifted its full-year outlook on Monday as the animal diagnostics and healt